Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surfactant replacement therapy--economic impact.

R K Pejaver1, I al Hifzi, S Aldussari

  • 1Devision of Neonatology, Northwest Armed Forces Hospital, P O Box 100, Tabuk, Saudi Arabia. pejaver@prism books.com

Indian Journal of Pediatrics
|July 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An audit of phototherapy units.

Indian journal of pediatrics·2001
Same author

Etretinate in the management of harlequin siblings.

Indian journal of pediatrics·2000
Same author

Appendicular perforation in necrotising enterocolitis.

Indian pediatrics·1998
Same author

Transfusion malaria in sick neonates.

Indian pediatrics·1998
Same author

Osteopenia of prematurity.

Indian pediatrics·1997
Same author

Major congenital malformations among Saudi infants admitted to Asir Central Hospital.

Annals of Saudi medicine·1997
Same journal

Bilateral Parotid Enlargement as an Initial Manifestation of Pediatric Acute Lymphoblastic Leukemia.

Indian journal of pediatrics·2026
Same journal

Hemorrhagic Cardiac Tamponade Due to MRSA Sepsis in a Child with Relapsed Acute Lymphoblastic Leukemia: Authors' Reply.

Indian journal of pediatrics·2026
Same journal

A Prospective Model for Detecting Missed Appendicitis in Low-Risk Pediatric Patients: Correspondence.

Indian journal of pediatrics·2026
Same journal

Serum Periostin as a Biomarker in Pediatric Asthma: Findings from a Case-Control Study - Authors' Reply.

Indian journal of pediatrics·2026
Same journal

When the Eye Peels: An Unusual Harbinger of Kawasaki Disease - Correspondence.

Indian journal of pediatrics·2026
Same journal

Pediatric Sleep-Related Laryngospasm: Cause of Nocturnal Respiratory Distress.

Indian journal of pediatrics·2026
See all related articles

Surfactant replacement therapy for neonatal respiratory distress syndrome (RDS) is cost-effective, reducing hospital stay and ventilation days. This treatment offers significant savings compared to non-surfactant management in neonatal intensive care units (NICUs).

Area of Science:

  • Neonatal Medicine
  • Health Economics

Background:

  • Neonatal respiratory distress syndrome (RDS) is a significant cause of infant mortality.
  • Surfactant replacement therapy has emerged as an effective treatment for RDS.
  • Assessing the economic impact of surfactant therapy is crucial for widespread adoption.

Purpose of the Study:

  • To compare the economic implications of surfactant replacement therapy versus conventional management for neonatal respiratory distress syndrome.
  • To evaluate the cost-effectiveness of surfactant therapy in a neonatal intensive care unit (NICU) setting.

Main Methods:

  • A comparative study was conducted at Northwest Armed Forces Hospital, Saudi Arabia.
  • 75 infants receiving surfactant for RDS were compared to 75 infants managed without surfactant.

Related Experiment Videos

  • Costs were calculated based on daily bed rates for different care levels, including equipment, salaries, overheads, medications, and procedures.

    • Main Results:

    • The surfactant group had shorter hospital stays (average 69.35 days vs. 89.69 days) and fewer ventilated days (15.65 vs. 26.60) compared to the non-surfactant group.
    • The average cost per infant was SR 118,009.75 for the surfactant group versus SR 164,070.70 for the non-surfactant group, representing a 39.03% cost saving.
    • 62 survivors in the surfactant group vs. 56 in the non-surfactant group.

    Conclusions:

    • Surfactant replacement therapy is a cost-effective intervention for neonatal respiratory distress syndrome.
    • The therapy leads to reduced healthcare resource utilization, including shorter hospital and ventilation durations.
    • NICU care with surfactant therapy demonstrates favorable cost per Quality Adjusted Life Year (QALY) compared to adult interventions.